Abbisko Advances KRAS G12D Cancer Program With First Patient Dosed in ABSK141 Trial

Abbisko Cayman Limited ( (HK:2256) ) has provided an announcement.

Abbisko Therapeutics, the oncology-focused subsidiary of Abbisko Cayman Limited, has advanced its pipeline with the first patient dosing in a Phase I/II trial of ABSK141, an oral, highly potent and selective small-molecule inhibitor targeting KRAS G12D mutations in advanced solid tumors. KRAS G12D, a predominant oncogenic mutation in pancreatic ductal adenocarcinoma, colorectal cancer and non-small cell lung cancer, has long been considered an undruggable target, with no approved therapies globally.

The study, cleared by both the U.S. FDA and China’s NMPA in December 2025, marks a key milestone in Abbisko’s effort to establish a foothold in KRAS-targeted therapy, an area of intense industry focus. Preclinical data suggest ABSK141 may offer best-in-class oral bioavailability and strong anti-tumor activity, positioning the program as a potentially transformative option for patients and reinforcing Abbisko’s ambitions to compete internationally in next-generation cancer treatments, though clinical and regulatory outcomes remain uncertain.

The most recent analyst rating on (HK:2256) stock is a Hold with a HK$13.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.

More about Abbisko Cayman Limited

Abbisko Cayman Limited, through its Shanghai-based subsidiary Abbisko Therapeutics, is an oncology-focused biopharmaceutical group dedicated to discovering and developing innovative precision oncology and immuno-oncology medicines for unmet medical needs in China and globally. Founded in 2016 by veterans from multinational pharmaceutical companies, it has built an extensive pipeline of novel targeted therapies, with a growing emphasis on small-molecule inhibitors for difficult cancer drivers.

Average Trading Volume: 1,493,495

Technical Sentiment Signal: Buy

Current Market Cap: HK$8.08B

Learn more about 2256 stock on TipRanks’ Stock Analysis page.